Sarepta prelim FY2023 net product rev $1.145B; ELEVIDYS $200.4M beats consensus

Sarepta Therapeutics, Inc.

2023-FY EPS reported -$5.80 revenue$1,243,336,000

Preliminary FY2023 total net product revenue of ~$1.145B; RNA PMOs $945.0M (above $925M guidance).
ELEVIDYS net product revenue of $131.3M in Q4 and $200.4M for FY2023, significantly exceeding consensus.
RNA-based PMO net revenue of $234.3M in Q4 and $945.0M for FY2023.
Preliminary cash, equivalents, restricted cash and investments of ~$1.7B as of Dec 31, 2023.
Company to report final Q4/FY2023 results in late February 2024; results subject to adjustment.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sarepta Therapeutics, Inc. reported the year ended December 31, 2023 results: revenue $1.145 billion.

Period: the year ended December 31, 2023
Revenue: $1.145 billion
Result: preliminary results

Exact text from the filing

the Company disclosed its (unaudited) cash position of approximately $1.7 billion as of December 31, 2023, and that the Company generated approximately $1.145 billion in total net product revenue (unaudited) in the year ended December 31, 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-002822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.